Astera Labs, Inc. $ALAB Shares Sold by National Pension Service

National Pension Service trimmed its stake in Astera Labs, Inc. (NASDAQ:ALAB) by 20.6% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 209,418 shares of the company’s stock after selling 54,402 shares during the quarter. National Pension Service’s holdings in Astera Labs were worth $101,153,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Royal Bank of Canada grew its position in shares of Astera Labs by 167.3% during the first quarter. Royal Bank of Canada now owns 152,453 shares of the company’s stock worth $9,097,000 after acquiring an additional 95,409 shares during the last quarter. AQR Capital Management LLC lifted its position in Astera Labs by 213.4% in the 1st quarter. AQR Capital Management LLC now owns 11,391 shares of the company’s stock valued at $680,000 after purchasing an additional 7,756 shares during the last quarter. Empowered Funds LLC boosted its stake in Astera Labs by 917.3% during the 1st quarter. Empowered Funds LLC now owns 4,639 shares of the company’s stock valued at $277,000 after purchasing an additional 4,183 shares during the period. First Trust Advisors LP boosted its stake in Astera Labs by 102.0% during the 2nd quarter. First Trust Advisors LP now owns 112,766 shares of the company’s stock valued at $10,196,000 after purchasing an additional 56,952 shares during the period. Finally, Brown Advisory Inc. grew its position in Astera Labs by 54.9% in the 2nd quarter. Brown Advisory Inc. now owns 5,581 shares of the company’s stock worth $505,000 after purchasing an additional 1,977 shares during the last quarter. Institutional investors and hedge funds own 60.47% of the company’s stock.

Insider Transactions at Astera Labs

In other news, Director Manuel Alba sold 183,000 shares of Astera Labs stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $280.13, for a total transaction of $51,263,790.00. Following the transaction, the director directly owned 253,863 shares in the company, valued at approximately $71,114,642.19. This trade represents a 41.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Philip Mazzara sold 6,801 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $340.50, for a total value of $2,315,740.50. Following the completion of the sale, the general counsel directly owned 96,542 shares in the company, valued at $32,872,551. This represents a 6.58% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 592,244 shares of company stock valued at $209,729,973 over the last three months. 10.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ALAB shares. Weiss Ratings restated a “hold (c)” rating on shares of Astera Labs in a research note on Tuesday, August 18th. Jefferies Financial Group boosted their price objective on Astera Labs from $270.00 to $450.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Roth Capital reissued a “buy” rating and issued a $450.00 price objective on shares of Astera Labs in a report on Wednesday, August 5th. Needham & Company LLC raised their target price on Astera Labs from $260.00 to $425.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, Evercore reaffirmed an “outperform” rating and set a $297.00 target price on shares of Astera Labs in a research note on Tuesday, May 19th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, Astera Labs has a consensus rating of “Moderate Buy” and a consensus target price of $348.33.

Astera Labs Trading Down 5.3%

Astera Labs stock opened at $284.53 on Friday. Astera Labs, Inc. has a 52 week low of $97.89 and a 52 week high of $499.48. The stock has a market cap of $49.36 billion, a price-to-earnings ratio of 140.86 and a beta of 3.77. The company’s 50-day moving average price is $318.90 and its two-hundred day moving average price is $259.95.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.11. The company had revenue of $392.40 million during the quarter, compared to analyst estimates of $360.85 million. Astera Labs had a net margin of 30.74% and a return on equity of 19.24%. The business’s revenue for the quarter was up 104.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.44 EPS. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. Research analysts expect that Astera Labs, Inc. will post 2.7 earnings per share for the current fiscal year.

Astera Labs Profile

Astera Labs, Inc is a fabless semiconductor company that develops connectivity solutions for cloud and artificial intelligence infrastructure. Its products are designed to help data-center operators, system manufacturers and other customers connect, expand and manage the high-speed components used in servers, storage systems and networking platforms.

The company’s portfolio includes PCI Express (PCIe) retimers and fabric switches, Compute Express Link (CXL) memory connectivity products, and Ethernet connectivity solutions.